Andrew D. C. LaFrence
2021 - Cancer Genetics
In 2021, Andrew D. C. LaFrence earned a total compensation of $673.8K as Chief Financial Officer at Cancer Genetics.
Compensation breakdown
| Option Awards | $397,589 |
|---|---|
| Salary | $244,212 |
| Other | $32,000 |
| Total | $673,801 |
LaFrence received $397.6K in option awards, accounting for 59% of the total pay in 2021.
LaFrence also received $244.2K in salary and $32K in other compensation.
Rankings
In 2021, Andrew D. C. LaFrence's compensation ranked 10,016th out of 12,405 executives tracked by ExecPay. In other words, LaFrence earned more than 19.3% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 10,016 out of 12,405 | 19th |
Division Services | 1,920 out of 2,289 | 16th |
Major group Health Services | 221 out of 252 | 12th |
Industry group Medical And Dental Laboratories | 63 out of 73 | 14th |
Industry Medical Laboratories | 63 out of 73 | 14th |
Source: SEC filing on June 14, 2022.
LaFrence's colleagues
We found three more compensation records of executives who worked with Andrew D. C. LaFrence at Cancer Genetics in 2021.